Fusion Antibodies (LSE:FAB) Total Liabilities : £0.47 Mil (As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Fusion Antibodies Total Liabilities?

Fusion Antibodies's Total Liabilities for the quarter that ended in Sep. 2024 was £0.47 Mil.

Fusion Antibodies's quarterly Total Liabilities increased from Sep. 2023 (£0.60 Mil) to Mar. 2024 (£0.63 Mil) but then declined from Mar. 2024 (£0.63 Mil) to Sep. 2024 (£0.47 Mil).

Fusion Antibodies's annual Total Liabilities declined from Mar. 2022 (£1.23 Mil) to Mar. 2023 (£0.94 Mil) and declined from Mar. 2023 (£0.94 Mil) to Mar. 2024 (£0.63 Mil).

Fusion Antibodies Total Liabilities Historical Data

The historical data trend for Fusion Antibodies's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fusion Antibodies Total Liabilities Chart

Fusion Antibodies Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Total Liabilities

Get a 7-Day Free Trial

1.23

1.08

1.23

0.94

0.63

Fusion Antibodies Semi-Annual Data
	Mar15	Mar16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24
Total Liabilities	Get a 7-Day Free Trial													1.41	0.94	0.60	0.63	0.47

Fusion Antibodies Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Fusion Antibodies's Total Liabilities for the fiscal year that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0.584	+	(0.023	+	0.02
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	0.63

Total Liabilities	=	Total Assets (A: Mar. 2024 )	-	Total Equity (A: Mar. 2024 )
	=	2.42	-	1.793
	=	0.63

Fusion Antibodies's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0.44	+	(0.009	+	0.02
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	0.47

Total Liabilities	=	Total Assets (Q: Sep. 2024 )	-	Total Equity (Q: Sep. 2024 )
	=	1.528	-	1.059
	=	0.47

Fusion Antibodies Total Liabilities Related Terms

Thank you for viewing the detailed overview of Fusion Antibodies's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Fusion Antibodies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fusion Antibodies PLC (LSE:FAB) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Springbank Road, Springbank Industrial Estate, Dunmurry, Belfast, GBR, BT17 0QL

Website

https://www.fusionantibodies.com

Fusion Antibodies PLC offers various antibody engineering services for all therapeutic and diagnostic antibody development stages. It is engaged in the research, development, and manufacturing of recombinant proteins, particularly in cancer and infectious diseases. Its services include antibody sequencing, antibody humanization, stable cell line development, monoclonal antibody production, and transient protein expression. Geographically company generates the majority of its revenue from North America.

Fusion Antibodies Headlines

From GuruFocus

626 Financial, LLC Buys 3, Sells 2 in 3rd Quarter

By GuruFocus Research GuruFocus Editor • 10-21-2022